CD4+/CD8+ ratio

Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis

Retrieved on: 
Wednesday, June 30, 2021

IBM is an autoimmune disease in which cytotoxic CD8+ T cells chronically attack muscle cells, leading to progressive weakness and severe disability.

Key Points: 
  • IBM is an autoimmune disease in which cytotoxic CD8+ T cells chronically attack muscle cells, leading to progressive weakness and severe disability.
  • The proprietary first in class ImmunoPET imaging agent allows non-invasive, whole-body imaging CD8+ T cells using positron emission tomography (PET).
  • The technology, initially designed to visualize these cells in cancer patients, can now provide a non-invasive assessment of the extent of infiltration of CD8+ T cells in skeletal muscle in IBM patients.
  • ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body.

AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients

Retrieved on: 
Thursday, September 17, 2020

SARS-CoV-2 continues to have a devastating impact on patients and families around the world,said David Hallal, Chairman and Chief Executive Officer of AlloVir.

Key Points: 
  • SARS-CoV-2 continues to have a devastating impact on patients and families around the world,said David Hallal, Chairman and Chief Executive Officer of AlloVir.
  • There is an increasing body of evidence about the important role of T cells in the bodys fight against COVID-19.
  • Early research suggests that T cells play an important role in the bodys fight against COVID-19.
  • Over 80% of hospitalized patients with COVID-19 are lymphopenic, with reduced CD8+ and CD4+ T cell counts.

VBI Vaccines Announces Biomarker Data From VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020

Retrieved on: 
Thursday, September 17, 2020

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced additional biomarker data from its ongoing Phase 1/2a study evaluating VBI-1901, the companys cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM) patients presented in an e-poster at The European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced additional biomarker data from its ongoing Phase 1/2a study evaluating VBI-1901, the companys cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM) patients presented in an e-poster at The European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • As with the previously announced CD4+/CD8+ ratio, a biomarker which may reflect the immunologic fitness of CD4+ T cells in recurrent GBM patients, these biomarkers will continue to be evaluated throughout the study.
  • This phase enrolled 18 recurrent GBM patients across three dose cohorts of VBI-1901: 0.4 g, 2.0 g, and 10.0 g.
    Enrollment completed in December 2018.
  • VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients

Retrieved on: 
Thursday, April 2, 2020

Patient test data reveals improvement in cytokines, IL-6, and a trend toward the normalization of the CD4/CD8 ratio.

Key Points: 
  • Patient test data reveals improvement in cytokines, IL-6, and a trend toward the normalization of the CD4/CD8 ratio.
  • The current data suggests a trend toward the restoration of immune function and mitigation of the cytokine storm.
  • This is consistent with prior laboratory results in the first four patients treated for COVID-19 with leronlimab.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.

ImaginAb to Present at Upcoming Investor and Scientific Conferences in May and June 2019

Retrieved on: 
Thursday, May 30, 2019

ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body.

Key Points: 
  • ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body.
  • These novel minibodies, used with widely available PET scan technology, illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity.
  • ImaginAb is also developing a pipeline for other targets in oncology.
  • CD8 ImmunoPET minibody [89Zr-Df-IAB22M2C] binds CD8 receptor on human T cells and is used for non-invasive PET imaging of CD8 T cells in patients.